Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer
Metrics: PDF 1697 views | HTML 2041 views | ?
Xiaobin Gu1, Xian-Shu Gao1, Ming Cui1, Mu Xie1, Chuan Peng1, Yun Bai1, Wei Guo2, Linjun Han2, Xiaodong Gu3, Wei Xiong4
1Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China
2Graduate School of Medicine, Hebei North University, Zhangjiakou, Hebei, China
3Department of Breast Cancer Radiotherapy, Tumor Hospital of Shanxi Provence, Taiyuan, China
4Department of Oncology, Tangshan People’s Hospital, Hebei, China
Xian-Shu Gao, email: firstname.lastname@example.org
Keywords: PLR, gastric cancer, biomarker, prognosis, meta-analysis
Received: March 29, 2016 Accepted: June 30, 2016 Published: July 08, 2016
The present study was aim to investigate the prognostic role of platelet to lymphocyte ratio (PLR) for patients with gastric cancer (GC) using meta-analysis. A total of 13 studies (14 cohorts) with 6,280 subjects were included. By pooling hazard ratios (HRs) and 95% confidence intervals (CIs) and odds ratios (ORs) and 95% CIs from each study, we found that elevated PLR was significantly associated with poorer overall survival (OS) (HR: 1.3, 95% CI: 1.1–1.52, p = 0.001; Ι² = 68.5%, Ph < 0.001) but not with poor disease-free survival (DFS) (HR: 1.6, 95% CI: 0.88–2.9, p = 0.122; I2 = 87.8%, Ph < 0.001). Subgroup analysis showed that a high PLR significantly predicted poor OS in Caucasian populations, patients receiving chemotherapy and patients at advanced stage. In addition, the cut-off value of PLR > 160 showed adequately prognostic value. Furthermore, elevated PLR was associated with lymph node metastasis and CEA levels in GC. Our meta-analysis showed that elevated PLR could be a significant prognostic biomarker for poor OS in patients with GC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.